Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Respiratory disease affects one in five people and is a leading cause of global morbidity and mortality. Chronic obstructive airways diseases encompass conditions characterised by expiratory airflow limitation, exertional dyspnoea, activity limitation and impaired quality of life. The most common conditions include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, cystic fibrosis and primary ciliary dyskinesia. In recent years, there has been concerted effort in the scientific and respiratory medicine community to improve the diagnosis and management of chronic obstructive airways diseases using personalised or precision medicine (i.e., tailoring therapies and interventions according to specific treatable traits) and identifying phenotypes or endotypes using validated biomarkers. To date, however, research in this setting has primarily focussed on people with COPD and asthma, with limited studies in other forms of chronic obstructive airways diseases. The aim of this study is therefore two-fold; first, to compare pulmonary physiology (i.e., large and small airway involvement) and extra-pulmonary manifestations across the spectrum of chronic obstructive airways, and second, to determine how disease-specific treatable traits associate with physical activity and health-related quality of life.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Prior diagnosis of airways disease in accordance with European Respiratory Society guidelines.

• Non / ex-smokers (packs recorded as cigarettes per day / years smoked).

• Male or female aged 18-65 years

• Ability to provide written informed consent.

• Full comprehension of spoken and written English language.

• Cystic Fibrosis patients on triple CFTR modulators (90% cohort)

• Cystic Fibrosis patients on no CFTR modulators

• Healthy controls - entirely asymptomatic, no prior history of inhaler medication use and free from respiratory disease.

Locations
Other Locations
United Kingdom
University of Leeds
RECRUITING
Leeds
Contact Information
Primary
Oliver Price, PhD
o.price1@leeds.ac.uk
01133437639
Time Frame
Start Date: 2023-10-01
Estimated Completion Date: 2025-07-31
Participants
Target number of participants: 100
Treatments
COPD
Asthma
Bronchiectasis
Cystic fibrosis
Primary ciliary dyskinesia
Sponsors
Collaborators: The Leeds Teaching Hospitals NHS Trust
Leads: University of Leeds

This content was sourced from clinicaltrials.gov